rimtuzalcap   Click here for help

GtoPdb Ligand ID: 12649

Synonyms: CAD-1883 | CAD1883 | compound 1 [US9975886B1]
Compound class: Synthetic organic
Comment: Rimtuzalcap (CAD-1883) is a KCa2 channel activator (positive allosteric modulator) [1], that was developed for potential to treat movement disorders such as essential tremor and spinocerebellar ataxia.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 64.82
Molecular weight 378.42
XLogP 2.43
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1=NN(C=C1)C2=NC(=CC(=N2)NC3CCC(CC3)(F)F)N4CCOCC4
Isomeric SMILES CC1=NN(C=C1)C2=NC(=CC(=N2)N3CCOCC3)NC4CCC(CC4)(F)F
InChI InChI=1S/C18H24F2N6O/c1-13-4-7-26(24-13)17-22-15(21-14-2-5-18(19,20)6-3-14)12-16(23-17)25-8-10-27-11-9-25/h4,7,12,14H,2-3,5-6,8-11H2,1H3,(H,21,22,23)
InChI Key OVLIDRAJVMUEMC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Rimtuzalcap (CAD-1883) was progressed to clinical studies to determine efficacy in essential tremor and spinocerebellar ataxia (SCA). It was granted FDA orphan drug designation for SCA in mid-2019. However, following Novartis' acquisition of Cadent Pharmaceuticals, the decision was made not to progress CAD-1883 further in SCA.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03688685 A Clinical Study to Evaluate CAD-1883 in Essential Tremor Phase 2 Interventional Cadent Therapeutics